Home › Funds › Simplify Health Care ETF
Fund family: Simplify Exchange Traded Funds · Filed by Simplify Exchange Traded Funds (CIK 1810747) · SEC series S000073751
Ticker: PINK (C000230898)
“With management” counts the items where the fund’s own filing gives management’s recommendation (FOR or AGAINST): 559 with, 18 against, 0 abstentions (not counted as with management). Shareholder proposals: 0 FOR, 15 AGAINST, 0 abstained, by the filing’s own vote-source field.
No item-level comparison with other Simplify Exchange Traded Funds funds is possible: no ballot item of this fund was voted by at least three other funds of the family with a clear majority.
The same votes as “with management” above, by the sector of the company voted on. 86.7% of this fund’s 577 such votes could be given a sector; the other 77 (13.3%) are at companies without one and are not in the table.
| Sector | Votes | Against management | Share |
|---|---|---|---|
| Health Care | 391 | 17 | 4.3% |
| Industrials | 72 | 0 | 0.0% |
| Consumer Discretionary | 20 | 0 | 0.0% |
| Consumer Staples | 17 | 1 | 5.9% |
| Proposal type | Items | Against management |
|---|---|---|
| Director Elections | 383 | 3 |
| Audit-related | 57 | 0 |
| Say-on-Pay | 52 | 0 |
| Compensation | 38 | 1 |
| Corporate Governance | 18 | 10 |
| Capital Structure | 15 | 0 |
| Shareholder Rights and Defenses | 13 | 3 |
| Other Social Issues | 2 | 1 |
Position = shares voted × a recent share price, for US-listed shares of companies with a page on this site; an estimate for ranking only.
| Company | Meeting | Est. position | Items | Against mgmt |
|---|---|---|---|---|
| ELI LILLY AND COMPANY | May 4, 2026 | $28M | 10 | 2 |
| UNITED THERAPEUTICS CORPORATION | June 26, 2026 | $20M | 15 | 0 |
| 10X GENOMICS, INC. | June 4, 2026 | $19M | 5 | 0 |
| ALIGN TECHNOLOGY, INC. | May 20, 2026 | $18M | 13 | 0 |
| ABBVIE INC. | May 8, 2026 | $15M | 8 | 1 |
| JOHNSON & JOHNSON | April 23, 2026 | $15M | 15 | 1 |
| THERMO FISHER SCIENTIFIC INC. | May 20, 2026 | $12M | 13 | 0 |
| GILEAD SCIENCES, INC. | April 30, 2026 | $11M | 15 | 3 |
| Meeting | Company | Proposal | Fund | Mgmt |
|---|---|---|---|---|
| May 4, 2026 | ELI LILLY AND COMPANY | Shareholder proposal to adopt a policy and amend the bylaws to require an independent board chair. Shareholder proposal | Against | For |
| May 4, 2026 | ELI LILLY AND COMPANY | Shareholder proposal to prepare an annual lobbying report. Shareholder proposal | Against | For |
| May 8, 2026 | ABBVIE INC. | Stockholder Proposal - to Adopt a Policy to Require an Independent Chair Shareholder proposal | Against | For |
| April 23, 2026 | JOHNSON & JOHNSON | Independent Board Chair Shareholder proposal | Against | For |
| April 30, 2026 | GILEAD SCIENCES, INC. | To vote on a stockholder proposal requesting an independent Board Chair policy, if properly presented at the Annual Meeting. Shareholder proposal | Against | For |
| April 30, 2026 | GILEAD SCIENCES, INC. | To vote on a stockholder proposal requesting a report on the impact of extended patent exclusivities on patient access, if properly presented at the Annual Meeting. Shareholder proposal | Against | For |
| May 19, 2026 | AMGEN INC. | Stockholder proposal to require an independent board chairman. Shareholder proposal | Against | For |
| May 13, 2026 | VERTEX PHARMACEUTICALS INCORPORATED | Shareholder proposal, if properly presented at the meeting, regarding shareholder right to act by written consent. Shareholder proposal | Against | For |
| May 14, 2026 | CVS HEALTH CORPORATION | Stockholder Proposal for Reducing the Threshold for Our Stockholder Right to Act By Written Consent. Shareholder proposal | Against | For |
| April 23, 2026 | IQVIA HOLDINGS INC. | If properly presented, a stockholder proposal concerning separate Chairman and Chief Executive Officer roles. Shareholder proposal | Against | For |
| June 9, 2026 | PACIRA BIOSCIENCES, INC. | DOMA Nominees Opposed by the Company: Oliver Benton Curtis III | Withhold | For |
| June 9, 2026 | PACIRA BIOSCIENCES, INC. | DOMA Nominees Opposed by the Company: Eric de Armas | Withhold | For |
Meetings with a proxy contest or competing nominees (1 in 2025-2026), and how the fund voted the items on its ballot.
578 ballot items at 57 meetings in 2025-2026. Download all votes (CSV)
Recent votes against management’s recommendation at large companies.
In the 2025-2026 proxy season, Simplify Health Care ETF (PINK) voted at 57 shareholder meetings of 55 companies, on 578 ballot items in all. Where management made a recommendation, the fund followed it on 96.9% of the items and voted against it 18 times. Its most frequent area of disagreement was corporate governance (10 of its votes against management). It voted on 15 shareholder proposals. 1 of its meetings was contested.
Every figure is derived from the fund’s own Form N-PX filings with the SEC, read item by item: one ballot item is the fund’s vote on one proposal at one meeting, and an item filed twice in the season is counted once. Percentages count items, never shares. A season is published only with at least 250 ballot items at 15 meetings. Built November 18, 2026. The interactive database shows the same votes company by company, with every other fund that voted.